This up-and-coming cancer treatment could be a $25 billion market opportunity — it’s already a hotbed for M&A

[ad_1]

Targeted radiopharmaceuticals, which deliver radiation directly into tumors, has caught the eye of big pharma.

[ad_2]

Source link